NCT06832839 Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease
| NCT ID | NCT06832839 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tiantan Hospital |
| Condition | Moyamoya Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 360 participants |
| Start Date | 2024-12-16 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 360 participants in total. It began in 2024-12-16 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to comprehensively evaluate the risk factors for cognitive decline in patients with moyamoya disease, identify imaging target areas associated with cognitive damage in the brain, and explore the changes in brain structure and functional networks resulting from cerebral revascularization, as well as their relationship with cognitive improvement.
Eligibility Criteria
Inclusion Criteria: * The admission cerebral angiography (DSA) examination fulfills the diagnostic criteria for moyamoya disease. * Please sign the informed consent form. * Participants must be between 18 and 60 years of age. Exclusion Criteria: * Patients with concurrent atherosclerosis, autoimmune diseases, meningitis, brain tumors, Down syndrome, craniocerebral trauma, prior radioactive head irradiation, or hyperthyroidism, which may result in secondary cerebrovascular lesions leading to symptoms associated with smoke syndrome. * Individuals younger than 18 years or older than 60 years. * Those with contraindications for magnetic resonance imaging. * Patients who are unable to complete cognitive brain assessments
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06832839 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Moyamoya Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06832839 currently recruiting?
Yes, NCT06832839 is actively recruiting participants. Contact the research team at zhangqianchina@yahoo.com for enrollment information.
Where is the NCT06832839 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06832839 clinical trial?
NCT06832839 is sponsored by Beijing Tiantan Hospital. The trial plans to enroll 360 participants.